The combination of interferon (IFN) and ribavirin is the current gold stand
ard for treatment of chronic hepatitis C virus (HCV) infection with sustain
ed remission rates of 35-40% being achieved in haemophilic patients. A simi
lar beneficial effect of this combined therapy has been suggested even for
patients with compensated liver cirrhosis and some authors have reported a
possible role for IFN and ribavirin in the prevention or delay in the devel
opment of hepatocellular carcinoma (HCC), a well known complication of HCV
infection in haemophiliacs. The absence, due to design difficulties, of def
inite randomized controlled clinical trials remains a handicap for the rout
ine use of specific therapy of HCV infected patients with the aim of preven
ting HCC. A discussion of these important issues has been performed in this
paper.